Completed PHASE1 INTERVENTIONAL 2-arm NCT02708576

Phase 1 Study of NGM313 in Healthy Adult Participants

A Phase 1 Randomized, Double Blind, Placebo Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NGM313 in Healthy Overweight and Obese Adult Participants

Sponsor: NGM Biopharmaceuticals, Inc

Conditions Obesity

Interventions NGM313 Placebo

Updated 8 times since 2017 Last updated: Sep 13, 2017 Started: Feb 29, 2016 Primary completion: Apr 30, 2017 Completion: Apr 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02708576, this PHASE1 trial focuses on Obesity and remains completed. Sponsored by NGM Biopharmaceuticals, Inc, it has been updated 8 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Oct 2017 — Jun 2018 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed

▶ Show 3 earlier versions

Apr 2017 — Oct 2017 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Feb 2017 — Apr 2017 [monthly]

Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

Feb 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NGM Biopharmaceuticals, Inc

Data source: NGM Biopharmaceuticals, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Melbourne, Australia